ERCC 多态性与骨肉瘤风险：一项荟萃分析。

ERCC polymorphisms and risk of osteosarcoma: a meta-analysis.

机构信息

The Department of Bone Diseases, Hong-Hui Hospital, Xi'an Jiaotong University College of Medicine, Xi'an, China.

出版信息

Eur Rev Med Pharmacol Sci. 2018 Oct;22(20):6658-6666. doi: 10.26355/eurrev_201810_16142.

DOI:10.26355/eurrev_201810_16142

PMID:30402838

Abstract

OBJECTIVE

The association between excision repair cross-complementation (ERCC) gene family (ERCC1 and ERCC2) and osteosarcoma risk was controversial. The aim of this study was to evaluate the association between ERCC1 or ERCC2 and osteosarcoma risk by systematic meta-analysis.

MATERIALS AND METHODS

Relative studies were retrieved from electronic databases without language restriction. The last search was updated on March 2017. Quality assessment was analyzed by the Newcastle-Ottawa Scale (NOS) score, which was recommended by the Agency for Healthcare Research and Quality (AHRQ). Meta-analysis was conducted by R language package (R 3.12).

RESULTS

This meta-analysis was performed based on 4 case-control studies that included 1208 cases and 2448 controls. The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.

CONCLUSIONS

The ERCC2 rs1799793 polymorphism is related to the high risk of osteosarcoma development.

摘要

目的

切除修复交叉互补基因家族（ERCC1 和 ERCC2）与骨肉瘤风险之间的关系存在争议。本研究旨在通过系统的荟萃分析来评估 ERCC1 或 ERCC2 与骨肉瘤风险之间的关联。

材料和方法

无语言限制地从电子数据库中检索相关研究。最后一次搜索更新于 2017 年 3 月。使用美国医疗保健研究与质量局（AHRQ）推荐的纽卡斯尔-渥太华量表（NOS）评分来分析质量评估。使用 R 语言包（R 3.12）进行荟萃分析。

结果

本荟萃分析基于 4 项病例对照研究，包括 1208 例病例和 2448 例对照。ERCC2-rs1799793 AA+AC > CC（OR=1.3428，95%CI=1.0201；1.7674）对骨肉瘤的发生风险有影响，而其他 ERCC SNPs（ERCC1 rs3212986、ERCC1 rs11615 和 ERCC2 rs13181）与骨肉瘤之间没有显著关联。